A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes

By L. Kennedy. 2007

680 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Surgery

View Paper: https://www.semanticscholar.org/paper/876c05fb69549a4f27ac506b2b1172200ae7d029

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. R. Bergenstal

Citations in the corpus

• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2012, background): “The latter two are associated with modestly less overnight hypoglycaemia (insulin glargine, insulin detemir) than NPH and possibly slightly less weight gain (insulin detemir), but are more expensive [75, 76].”
• CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016, background): “Although insulin analogs and NPH have been shown to be equally effective in reducing A1C in clinical trials, insulin analogs caused significantly less hypoglycemia (123-127).”